GANTANOL
LOE ApproachingNDAORALSUSPENSION
Approved
Jul 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANTANOL is an oral suspension small-molecule product approved by Roche in 1965 with unknown mechanism of action and indication profile. Generic composition and pharmacologic class remain unspecified in available data.
LOE Approaching
Approaching loss of exclusivity signals wind-down or transition activities; branded team likely focused on authorized generic or lifecycle management strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring; this product offers limited career advancement opportunity. Role focus is on defensive strategies and market maintenance rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on GANTANOL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.